Copy For Citation
Gunaldi M., Duman B. B., Afsar C. U., PAYDAŞ S., Erkisi M., KARA İ. O., ...More
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.22, no.2, pp.242-247, 2016 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
22
Issue:
2
-
Publication Date:
2016
-
Doi Number:
10.1177/1078155214567162
-
Journal Name:
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.242-247
-
Keywords:
Trastuzumab, breast cancer, cardiotoxicity, onco-pharmacology, risk factors, ADJUVANT TRASTUZUMAB, CARDIAC DYSFUNCTION, THERAPY, DOXORUBICIN
-
Çukurova University Affiliated:
Yes
Abstract
Background: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic.